APA (7th ed.) Citation

Campone, M., Bondarenko, I., Brincat, S., Hotko, Y., Munster, P. N., Chmielowska, E., . . . Epstein, R. J. (2012). Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Annals of Oncology, 23(3), 610. https://doi.org/10.1093/annonc/mdr261

Chicago Style (17th ed.) Citation

Campone, M., et al. "Phase II Study of Single-agent Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, in Patients with Locally Advanced or Metastatic Breast Cancer Pretreated with Chemotherapy." Annals of Oncology 23, no. 3 (2012): 610. https://doi.org/10.1093/annonc/mdr261.

MLA (9th ed.) Citation

Campone, M., et al. "Phase II Study of Single-agent Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, in Patients with Locally Advanced or Metastatic Breast Cancer Pretreated with Chemotherapy." Annals of Oncology, vol. 23, no. 3, 2012, p. 610, https://doi.org/10.1093/annonc/mdr261.